Giorgio Barbarini

Pavia, 27100, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Women Living with HIV in Italian Prison Settings: Results from the Gender-Specific ROSE Network.

Women Living with HIV in Italian Prison Settings: Results from the Gender-Specific ROSE Network.

Journal: Viruses
Published: November 22, 2022

Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience.

Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience.

Journal: The American journal of gastroenterology
Published: July 31, 2020

Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study.

Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study.

Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: April 27, 2020

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study.

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study.

Journal: Drugs in context
Published: April 04, 2020

Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs.

Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs.

Journal: Viruses
Published: January 24, 2020

Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.

Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.

Journal: HIV clinical trials
Published: March 21, 2019

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations.

Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations.

Journal: Infection and drug resistance
Published: February 14, 2019

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.

Journal: Gut and liver
Published: June 11, 2018

Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.

Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.

Journal: The Annals of pharmacotherapy
Published: February 28, 2018

Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy.

Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy.

Journal: The International journal on drug policy
Published: January 14, 2018

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.

Journal: BMC infectious diseases
Published: June 21, 2017

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.

Journal: Scientific reports
Published: May 22, 2017
Showing 1-12 of 28

Last Updated: 09/26/2026